Allogene Therapeutics Inc.
11/13/2024 | Press release | Distributed by Public on 11/13/2024 15:30
Material Event Form 8 K
Item 8.01 Other Events.
On November 11, 2024, Allogene Therapeutics, Inc. (the "Company") decided to discontinue enrollment in its Phase 1 cohort in the ALPHA2 clinical trial to evaluate cemacabtagene ansegedleucel ("cema-cel") as a treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) in patients previously treated with BTKi and BCL2i therapies. While there is an ongoing need for additional treatment options for these patients, and interest in this cohort remains high among investigators, enrollment in the trial has been slower than anticipated due in part to the emergence of new alternative treatment options. Consequently, the Company is discontinuing enrollment in this trial and reallocating resources to other programs.